Skip to content

COVID-19 associated neuropathy and myopathy in Germany.

COVID-19 associated neuropathy and myopathy in Germany. - COUP19

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00021677
Enrollment
200
Registered
2020-05-11
Start date
2021-04-26
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1 G63.0 G73.7

Interventions

Group 1: Patients after COVID-19 with persistent neuromuscular symptoms first answer standardized questionnaires and are examined neurologically and neuropyhsiologically. After 3,6,9 and 12 months the

Sponsors

Klinik für Anästhesiologie, Intensiv- und Schmerzmedizin; Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: age = 18 years, voluntary participation, written informed consent for apparative examination, fluency in German language, positive PCR test for SARS-CoV-2 within the last 6 months, >14 days free on COVID-19-symptoms or two negative PCR tests

Exclusion criteria

Exclusion criteria: participants who are unable to provide information due to language barrier, psychological or somatic reasons, single contraindications for one of the performed tests (which are then spared)

Design outcomes

Primary

MeasureTime frame
Prevalence of neuromuscular symptoms after COVID-19 (based on the initial online or telephone interview and in the course of up to 12 months)

Secondary

MeasureTime frame
Prevalence of functional and/or morphological affection of small and large nerve fibers and muscles after COVID-19 (based on neurophysiological examinations within 6 months after COVID-19 and possibly 6 months after the initial examination)

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026